Mary  Kelley

Dr. Kelley has worked with the Emory Psychiatry department studying the biological predictors (imaging, genetics, immune) of treatment response in depression. She is well-versed in the challenges of research involving complex behavioral assessments and evaluation of interventions in behaviorally disordered patients, and has an extensive background in statistical analysis relevant to studies of human behavior including clinical trials of psychopharmacological therapies, scale/survey development and evaluation, and imaging applications in psychiatric research. In addition to the studies in depression treatment, she is currently involved in a study of the effects of substance use and early life events in first episode schizophrenia patients, as well as a trial of a new outpatient treatment for the severely mentally ill (SMI) with this diagnosis.  Dr. Kelley also has extensive experience in health services research having worked for at the Center for Health Equity and Research Promotion (CHERP - VA Pittsburgh) for 6 years. At that time, she was involved in a number of studies on subjects with CHD including assessment of treatment practices, the effects of alcohol use, and predictive risk models for cardiovascular outcomes. She most recently has re-entered health services research as the Director of Biostatistics for the Division of Informatics and Health Services Research in the Department of Anesthesiology, School of Medicine.  These studies are currently focused on predictive models for short term mortality in ICU patients, using high fidelity minute to minute data from TeleICU. Her methodology work evolves from her extensive experience with categorical (primarily ordinal) data, and is focused on the issues of non-response evident in many behavioral scales that result in “zero inflation”, use of ordinal data in the development of latent constructs, and assessment of longitudinal response.